drugset
drugset / Trial / NCT04000594

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

NCT04000594 ↗

Phase 1 Completed 12 enrolled Hoffmann-La Roche
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response to RO7234292 (RG6042) treatment after intrathecal (IT) administration of RO7234292 (RG6042) to patients with manifest Hungtington's disease (HD).

Timeline

Start
2019-09-02
Primary completion
2022-01-18
Completion
2022-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject RO7234292 Unknown — Intrathecal

Indications

Huntington disease